Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chimeric fusion proteins--diphtheria toxin-based.

A E Frankel1, B L Powell, D A Vallera

  • 1Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA. afrankel@wfubmc.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|November 23, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

No evidence for microsatellite instability in acute myeloid leukemia.

Leukemia·2017
Same author

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.

Leukemia·2017
Same author

Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.

Leukemia·2016
Same author

Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.

Leukemia·2016
Same author

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).

Leukemia·2016
Same author

Vascular ring presenting as dysphagia in an adult woman: a case report.

Annals of the Royal College of Surgeons of England·2016

Novel anticancer therapies targeting protein synthesis are needed to overcome drug resistance. This review examines engineered diphtheria toxin (DT) conjugates for selective tumor cell targeting and intoxication.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Chemotherapy resistance is a major challenge in cancer treatment, necessitating novel therapeutic strategies.
  • Targeting tumor cell protein synthesis offers an alternative approach to overcome multidrug resistance.
  • Diphtheria toxin (DT) is a peptide toxin that inhibits protein synthesis and has been extensively studied for protein engineering.

Purpose of the Study:

  • To review the structure, function, synthesis, and pharmacology of anticancer diphtheria toxin (DT) conjugates.
  • To explore the potential of engineered DT as a targeted cancer therapy.
  • To discuss methods for overcoming drug resistance by targeting protein synthesis.

Main Methods:

  • Review of existing literature on diphtheria toxin structure, function, and engineering.

Related Experiment Videos

  • Analysis of studies on the development and application of DT conjugates in cancer research.
  • Examination of pharmacological data related to DT-based anticancer agents.

    • Main Results:

    • Diphtheria toxin (DT) can be engineered to selectively target and intoxicate cancer cells.
    • Anticancer DT conjugates demonstrate potential in overcoming multidrug resistance.
    • Structural and genetic modifications have enhanced the specificity and efficacy of DT-based therapies.

    Conclusions:

    • Engineered diphtheria toxin (DT) conjugates represent a promising strategy for targeted cancer therapy.
    • Targeting protein synthesis with DT offers a viable alternative to conventional chemotherapy.
    • Further research into the pharmacology and clinical application of DT conjugates is warranted.